Andrew Vickers

Author PubWeight™ 99.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008 5.09
2 Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010 3.76
3 Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc 2009 3.04
4 Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009 3.00
5 Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 2014 2.61
6 Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009 2.47
7 Complications after radical and partial nephrectomy as a function of age. J Urol 2010 2.36
8 Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012 2.28
9 Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol 2011 2.22
10 Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst 2014 2.16
11 Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2010 1.91
12 Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol 2007 1.88
13 Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol 2009 1.78
14 Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol 2013 1.73
15 Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer. Eur Urol 2006 1.67
16 Timing of curative treatment for prostate cancer: a systematic review. Eur Urol 2013 1.63
17 Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan. Leuk Res 2005 1.59
18 Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol 2006 1.50
19 Randomized controlled trial of a special acupuncture technique for pain after thoracotomy. J Thorac Cardiovasc Surg 2008 1.49
20 Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol 2012 1.47
21 Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016 1.47
22 Acupuncture for the prevention of tension-type headache. Cochrane Database Syst Rev 2016 1.46
23 Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol 2008 1.43
24 [Does use of alternative medicine aggravate the survival prognosis in cancer?]. Tidsskr Nor Laegeforen 2003 1.40
25 Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005 1.32
26 The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol 2010 1.30
27 A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak 2010 1.23
28 Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002 1.22
29 Integrative Oncology Practice Guidelines. J Soc Integr Oncol 2007 1.21
30 Multimorbidity and evidence generation. J Gen Intern Med 2014 1.17
31 Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006 1.17
32 Treating metastatic disease: Which survival model is best suited for the clinic? Clin Orthop Relat Res 2013 1.17
33 Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal 2007 1.12
34 Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010 1.12
35 Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007 1.09
36 Four-hundredfold overestimation of biopsy mortality. BJU Int 2013 1.07
37 Re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87: statistical concerns with Briganti radiotherapy analysis. Eur Urol 2013 1.06
38 The status and future of acupuncture clinical research. J Altern Complement Med 2008 1.06
39 How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through. Stat Med 2014 1.03
40 A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010 1.03
41 Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol 2016 1.00
42 Prediction models in urology: are they any good, and how would we know anyway? Eur Urol 2009 0.96
43 Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. Int J Urol 2007 0.94
44 Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 2008 0.94
45 Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer 2006 0.93
46 Natural history of positive urinary cytology after radical cystectomy. J Urol 2006 0.93
47 Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn 2007 0.93
48 Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol 2015 0.91
49 Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemother Pharmacol 2009 0.91
50 Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer 2006 0.89
51 A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. J Ethnopharmacol 2011 0.88
52 Evaluation of prediction models for decision-making: beyond calibration and discrimination. PLoS Med 2013 0.87
53 Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract. J Urol 2006 0.83
54 What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public? Urol Oncol 2010 0.83
55 Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 2005 0.83
56 Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy. Eur Urol 2006 0.82
57 Placebo in acupuncture trials. Pain 2004 0.82
58 Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Support Care Cancer 2013 0.80
59 How many lymphadenectomies does it take to cure one patient? Eur Urol 2007 0.80
60 Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology 2013 0.80
61 A phase II, randomized, controlled trial of acupuncture for reduction of Postcolectomy Ileus. Ann Surg Oncol 2012 0.80
62 Spotlight on prostate cancer: the latest evidence and current controversies. BMC Med 2015 0.79
63 Positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy. Eur Urol 2005 0.78
64 Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology 2006 0.78
65 WITHDRAWN: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2014 0.78
66 Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int 2012 0.78
67 Five genetic variants associated with prostate cancer. N Engl J Med 2008 0.77
68 Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. J Clin Oncol 2007 0.77
69 Acupuncture: integration into cancer care. J Soc Integr Oncol 2006 0.77
70 Evaluation of specific and non-specific effects in homeopathy: feasibility study for a randomised trial. Homeopathy 2006 0.76
71 Point-counterpoint: using clinical trials for the evaluation of integrative cancer therapies. Integr Cancer Ther 2004 0.75
72 Widespread body pain and mortality. Theories that psychological states cause cancer should be rejected. BMJ 2002 0.75
73 Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol 2014 0.75
74 Acupuncture for migraine prophylaxis. Sao Paulo Med J 2015 0.75
75 What do we mean by "outcome can be predicted"? Am Heart J 2008 0.75
76 Recent review of research on a technique for treating cancer. Integr Cancer Ther 2004 0.75
77 Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Eur Urol 2013 0.75
78 Editorial comment. Urology 2011 0.75
79 Screening for prostate cancer. Ann Intern Med 2012 0.75
80 Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol 2017 0.75